Company’s first development candidate in autoimmune and inflammatory disease (AIID) demonstrates potent blockade of IL-4, IL-13, and IL-33 signaling pathways critical in respiratory inflammationNovel ...

Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced today that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable ...

- Research agreement is evaluating feasibility of applying Rani's oral delivery technology to Chugai's antibodies against ...

Global Implantable Infusion Pump Market Set for Steady Growth from 2022 to 2032, Driven by Chronic Disease Management and Technological Advances.

The autoinjector offers potential pain relief and is designed for self-administration, eliminating the need for refrigeration ...

Future Prospects: The future of the Vietnam intravenous system access devices market looks promising. As healthcare services expand and medical technology advances, the demand for reliable and safe IV ...

Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...